Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona.


Journal

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 04 12 2018
accepted: 10 12 2018
pubmed: 5 1 2019
medline: 21 12 2019
entrez: 5 1 2019
Statut: ppublish

Résumé

Evidence suggests an excess of long-term mortality due to cardiovascular diseases, second tumours and other causes in patients diagnosed with invasive breast cancer (BC). Our aim was to assess this risk of death in a cohort of patients diagnosed with BC in Girona and Tarragona, northeastern Spain. Using data from the cancer registries in these areas, a population-based cohort study was carried out including all the women diagnosed with BC during 1985-2004 and followed up until December 31st 2014 (N = 10,195). The standardised mortality ratios (SMRs) were calculated for causes other than BC in the cohort at 10 years (periods 1985-1994/1995-2004) and 20 years (period 1985-1994). The impact of competing causes of death in the long-term survival was evaluated through competing risk analysis. The SMRs at 10 and 20 years for all-cause mortality, except BC, were 1.21 and 1.22. The main causes of mortality showing statistically significant SMR at 10 years were other tumours (colon, lung, corpus uteri, ovary, and haematological), diabetes mellitus, diseases of the nervous system, cardiovascular diseases (after BC, the second competing cause of death among patients diagnosed > 69 years) and diseases of the kidney. Globally, the 10-year SMR was higher in the first period. After 20 years of follow-up (1985-1994 cohort), there were 48.5 excess deaths per 10,000 patient-years for causes other than BC. Women who did not die from BC at 10 or 20 years after the BC diagnosis had 20% higher risk of dying from other causes than women without BC. This excess risk must be clinically considered during 20 years after the BC diagnosis.

Identifiants

pubmed: 30607790
doi: 10.1007/s12094-018-02015-5
pii: 10.1007/s12094-018-02015-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1014-1025

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI14/01041
Organisme : Ag'ncia d'Avaluació d'Universitats i Recerca
ID : 2017SGR00735

Références

Lancet. 1999 May 15;353(9165):1641-8
pubmed: 10335782
Lancet. 2000 May 20;355(9217):1757-70
pubmed: 10832826
Cancer. 2001 Jul 1;92(1):172-80
pubmed: 11443624
Med Klin (Munich). 2004 Sep 15;99(9):506-17
pubmed: 15372180
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Int J Cancer. 2006 May 1;118(9):2285-92
pubmed: 16342146
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1081-91
pubmed: 16446057
BMC Cancer. 2007 Jan 15;7:9
pubmed: 17224064
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):501-7
pubmed: 18374500
Med Clin (Barc). 2008 Oct;131 Suppl 1:53-7
pubmed: 19080816
Br J Cancer. 2010 Jan 5;102(1):220-6
pubmed: 19935795
J Clin Oncol. 2011 Oct 20;29(30):4014-21
pubmed: 21911717
Int J Cancer. 2013 May 15;132(10):2404-12
pubmed: 23047687
Gynecol Oncol. 2013 Aug;130(2):340-5
pubmed: 23648471
J Surg Res. 2013 Sep;184(1):260-4
pubmed: 23688790
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Breast Cancer Res Treat. 2015 Apr;150(2):439-45
pubmed: 25764167
Acta Diabetol. 2016 Feb;53(1):99-107
pubmed: 25916213
Epidemiology. 2016 Jan;27(1):6-13
pubmed: 26414938
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1061-72
pubmed: 27026313
Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries:S85-S91
pubmed: 28005610
Clin Transl Oncol. 2017 Jul;19(7):799-825
pubmed: 28093701
Gastrointest Endosc. 2017 Sep;86(3):429-441.e1
pubmed: 28433614
Clin Transl Oncol. 2018 Feb;20(2):201-211
pubmed: 28718071
Clin Transl Oncol. 2018 Oct;20(10):1252-1260
pubmed: 29511947
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Natl Cancer Inst Monogr. 1985 Dec;68:99-112
pubmed: 4088315
J Natl Cancer Inst. 1994 Apr 6;86(7):527-37
pubmed: 8133536

Auteurs

A Ameijide (A)

Registre de Càncer de Tarragona, Fundació per a la investigació i la prevenció del Càncer (FUNCA), IISPV, Reus, Spain.

R Clèries (R)

Pla Director d'Oncologia, IDIBELL, Hospitalet de Llobregat, Spain. r.cleries@iconcologia.net.
Department de Ciències Clíniques, Universitat de Barcelona, Barcelona, Spain. r.cleries@iconcologia.net.

M Carulla (M)

Registre de Càncer de Tarragona, Fundació per a la investigació i la prevenció del Càncer (FUNCA), IISPV, Reus, Spain.

M Buxó (M)

Institut d'Investigació Biomèdica de Girona, IDIBGI, Parc Hospitalari Martí i Julià, Salt, Spain.

R Marcos-Gragera (R)

Registre de Càncer de Girona-Unitat d'Epidemiologia, Pla Director d'Oncologia, Institut Català d'Oncologia, Grup d'Epidemiologia Descriptiva, Genètica i Prevenció del Càncer de Girona-IDIBGI, Girona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Carlos III Institute of Health, Av/Monforte de Lemos, 5, 28029, Madrid, Spain.

J M Martínez (JM)

Departamento de Investigación y Análisis de Prestaciones, MC MUTUAL, Barcelona, Spain.
Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya, Barcelona, Spain.
Public Health Research Group, University of Alicante, Alicante, Spain.

M L Vilardell (ML)

Registre de Càncer de Girona-Unitat d'Epidemiologia, Pla Director d'Oncologia, Institut Català d'Oncologia, Grup d'Epidemiologia Descriptiva, Genètica i Prevenció del Càncer de Girona-IDIBGI, Girona, Spain.

M Vilardell (M)

Secció d'Estadística del Departament de Genètica, Microbiología i Estadística de la Facultat de Biología, Universitat de Barcelona, Barcelona, Spain.

J A Espinàs (JA)

Pla Director d'Oncologia, IDIBELL, Hospitalet de Llobregat, Spain.

J M Borràs (JM)

Pla Director d'Oncologia, IDIBELL, Hospitalet de Llobregat, Spain.
Department de Ciències Clíniques, Universitat de Barcelona, Barcelona, Spain.

Á Izquierdo (Á)

Registre de Càncer de Girona-Unitat d'Epidemiologia, Pla Director d'Oncologia, Institut Català d'Oncologia, Grup d'Epidemiologia Descriptiva, Genètica i Prevenció del Càncer de Girona-IDIBGI, Girona, Spain.
Departament d'Oncologia Médica, Institut Català d'Oncologia, Hospital Universitari Doctor Josep Trueta, Girona, Spain.

J Galceran (J)

Registre de Càncer de Tarragona, Fundació per a la investigació i la prevenció del Càncer (FUNCA), IISPV, Reus, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH